Back
Science

New Australian Clinical Guideline for Acute Coronary Syndromes Released

Generated on: Last updated: 1 sources
View source

New Australian Clinical Guideline for Acute Coronary Syndromes (ACS) Unveiled for 2025

A summary of the new Australian clinical guideline for diagnosing and managing acute coronary syndromes (ACS) for 2025 has been published in the Medical Journal of Australia. This guideline establishes an updated clinical standard for ACS diagnosis and management in Australia, replacing the 2016 guideline.

This marks the first major update in nearly a decade, setting a new benchmark for ACS care.

Core Recommendations and Updates

The new guideline introduces critical updates across various aspects of ACS diagnosis and management:

  • New terminology and a revised definition of myocardial infarction.
  • Recognition of electrocardiogram (ECG) patterns for acute coronary occlusion myocardial infarction (ACOMI) beyond ST-segment elevation.
  • Utilization of clinical decision pathways that incorporate high-sensitivity cardiac troponin (hs-cTn) assays for risk assessment.
  • Increased emphasis on the optimal timing of primary percutaneous coronary intervention in individuals with ST-segment elevation myocardial infarction (STEMI).
  • Use of intravascular imaging-guided percutaneous coronary intervention in individuals with non-ST-segment elevation acute coronary syndromes (NSTEACS).
  • Treatment guidance for specific patient groups, including those with cardiogenic shock, multivessel disease, or spontaneous coronary artery dissection.
  • Recommendations for the timing of platelet P2Y12 inhibitor administration in STEMI and NSTEACS.
  • More detailed advice on post-discharge care, including cardiac rehabilitation, secondary prevention programs, medicine adherence strategies, vaccinations, and screening for mental health conditions.
  • Treatment algorithms for tailored prescribing of antiplatelet and anticoagulation therapies.
  • A new recommended treatment target for low-density lipoprotein cholesterol (LDL-C).
  • New recommendations on specific medicines, including PCSK9 inhibitors, β-blockers, and angiotensin receptor-neprilysin inhibitors.

Key Changes in Clinical Practice

The guideline introduces significant shifts in medical practice, aiming for more refined and personalized patient care.

Key changes include broader recognition of ECG patterns for ACOMI, integrated high-sensitivity cardiac troponin (hs-cTn) testing into clinical decision pathways, and selective use of intravascular imaging in NSTEACS. Updates to P2Y12 inhibitor timing, stricter LDL-C targets, and the inclusion of PCSK9 inhibitor use are also prominent.

These comprehensive updates support more tailored and evidence-based approaches to both the immediate management and secondary prevention of ACS.